For the first phase of this study (phase I), the purpose will be to find the dose of a new
drug, BKM120, that can safely be given in combination with standard dose panitumumab.
For the second phase of this study (phase II), the purpose is to find out what effects the
combination of BKM120 and panitumumab, in doses found to be safe in the first part of the
study, has on patients and their colorectal cancer.